| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
19,560,000 |
| Market
Cap: |
195.60(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.89 - $14.75 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 21.3 |
| Insider 3/6 Months : 21.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Solid Biosciences is engaged in curing Duchenne muscular dystrophy (Duchenne), a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are Co.'s gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. Co.'s SGT-001 and SGT-003 vectors are derived from a naturally occurring, non-pathogenic virus called adeno-associated virus, which were selected for their ability to enter skeletal, diaphragm and cardiac muscle tissues.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
4,314,873 |
4,314,873 |
4,314,873 |
| Total Buy Value |
$0 |
$23,861,248 |
$23,861,248 |
$23,861,248 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
35,077 |
35,077 |
37,528 |
| Total Sell Value |
$0 |
$122,185 |
$122,185 |
$139,259 |
| Total People Sold |
0 |
7 |
7 |
8 |
| Total Sell Transactions |
0 |
8 |
8 |
12 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ganot Ilan |
|
– • – |
2023-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,583 |
90,924 |
|
- |
|
| Howton David T |
Chief Operating Officer |
• – – |
2023-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,051 |
13,051 |
|
- |
|
| Smith Ian F |
|
– • – |
2023-10-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,569 |
84,378 |
|
- |
|
| Ganot Ilan |
|
– • – |
2023-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,583 |
89,341 |
|
- |
|
| Smith Ian F |
|
– • – |
2023-07-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,570 |
68,809 |
|
- |
|
| Ganot Ilan |
Director |
– • – |
2023-06-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,583 |
87,758 |
|
- |
|
| Ganot Ilan |
Director |
– • – |
2023-05-02 |
4 |
AS |
$4.85 |
$2,364 |
I/I |
(487) |
4,153 |
|
-37% |
|
| Ganot Ilan |
Director |
– • – |
2023-05-02 |
4 |
OE |
$0.00 |
$0 |
I/I |
1,553 |
4,640 |
|
- |
|
| Smith Ian F |
Director |
– • – |
2023-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,569 |
53,239 |
|
- |
|
| Ganot Ilan |
Director |
– • – |
2023-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,584 |
86,175 |
|
- |
|
| Ganot Ilan |
Director |
– • – |
2023-01-27 |
4 |
AS |
$7.49 |
$10,351 |
D/D |
(1,382) |
84,591 |
|
-18% |
|
| Ganot Ilan |
Director |
– • – |
2023-01-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,883 |
85,973 |
|
- |
|
| Ganot Ilan |
Director |
– • – |
2023-01-27 |
4 |
AS |
$7.49 |
$1,056 |
I/I |
(141) |
1,378 |
|
-18% |
|
| Ganot Ilan |
Director |
– • – |
2023-01-27 |
4 |
OE |
$0.00 |
$0 |
I/I |
388 |
1,519 |
|
- |
|
| Morris Carl Ashley |
Chief Scientific Officer |
• – – |
2023-01-27 |
4 |
AS |
$7.49 |
$3,303 |
D/D |
(441) |
19,760 |
|
-18% |
|
| Morris Carl Ashley |
Chief Scientific Officer |
• – – |
2023-01-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,233 |
20,201 |
|
- |
|
| Smith Ian F |
Director |
– • – |
2023-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,620 |
37,670 |
|
- |
|
| Edelman Joseph |
Director |
– • • |
2022-12-02 |
4 |
A |
$0.00 |
$15,249,996 |
I/I |
2,601,763 |
73,107 |
|
- |
|
| Bcip Life Sciences Associates, Lp |
10% Owner |
– – • |
2022-12-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,130,423 |
|
-25% |
|
| Koppel Adam |
Director |
– • • |
2022-12-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,130,423 |
|
-25% |
|
| Cumbo Alexander |
President and CEO |
• • – |
2022-12-02 |
4 |
A |
$0.00 |
$0 |
D/D |
584 |
584 |
|
- |
|
| Smith Ian F |
Director |
– • – |
2022-12-02 |
4 |
A |
$0.00 |
$0 |
D/D |
13,172 |
356,380 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2022-12-02 |
4 |
A |
$0.00 |
$15,249,996 |
I/I |
2,573,193 |
109,661 |
|
- |
|
| Smith Ian F |
Director |
– • – |
2022-10-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,312 |
343,208 |
|
- |
|
| Smith Ian F |
Director |
– • – |
2022-07-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,313 |
318,896 |
|
- |
|
131 Records found
|
|
Page 2 of 6 |
|
|
0.10 (0.99%) 
